Phaseline

Targets › BTN3A

BTN3A: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: the race on BTN3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImCheck Therapeutics, an Ipsen companyICT01
humanized anti-BTN3A monoclonal antibody
BTN3APhase 1Solid Tumor, AdultOct 2027

Conditions

Solid Tumor, Adult (1)

Modalities

protein or peptide (1)

Companies

ImCheck Therapeutics, an Ipsen company (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.